Evidence map›Paper›PMID 41416837›Full record

ArticleJournal of virology2026

Stealth replication of SARS-CoV-2 Omicron in the nasal epithelium at physiological temperature.

Bárbara F Fonseca, Rémy Robinot, Vincent Michel, Akram Mendez, Samuel Lebourgeois, Chloé Chivé, Raphaël Jeger-Madiot, Roshan Vaid, Vincent Bondet, Elizabeth Maloney and 6 more

Abstract read
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Bárbara F FonsecaControl of Chronic Viral Infections Group, Virus & Immunity Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0001-6403-4099
Rémy Robinot *Control of Chronic Viral Infections Group, Virus & Immunity Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-3651-0171
Vincent Michel *Pathogenesis of Vascular Infections Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-7025-4343
Akram MendezDepartment of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0001-9195-3808
Samuel LebourgeoisControl of Chronic Viral Infections Group, Virus & Immunity Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-5966-427X
Chloé ChivéControl of Chronic Viral Infections Group, Virus & Immunity Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0009-0008-8848-4770
Raphaël Jeger-MadiotControl of Chronic Viral Infections Group, Virus & Immunity Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0009-0009-3444-8536
Roshan VaidDepartment of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-2074-5080
Vincent BondetTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-6534-0984
Elizabeth MaloneyTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-5023-8573
Florence Guivel-BenhassineVirus & Immunity Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0003-3410-5671
Olivier SchwartzVirus & Immunity Unit, Institut Pasteur, Université Paris Cité, Paris, France.
Darragh DuffyTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-8875-2308
Tanmoy MondalDepartment of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0001-6228-8001
Samy GobaaBiomaterials and Microfluidics core facility, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-0125-8674
Lisa A ChakrabartiControl of Chronic Viral Infections Group, Virus & Immunity Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-1895-3630

Funding

ANRS-MIE ECTZ213626 PERSICOT projectANRS-MIE fellowship SLFondation de France Tous Unis COVID project PR-166156France 2030 ANRS-23-PEPR-MIE 3D-LUNGO projectFrance 2030 ANRS-23-PEPR-MIE 3D-LUNGO projectANRS-23-PEPR_MIEFrance 2030 fellowship CCInstitut Pasteur COVID-19 RP call - COROCHIPInstitut Pasteur Steroid Response projectInstitut Pasteur Urgence COVID-19 Fundraising Campaign, PFR7 projectSidaction fellowship RRStiftelsen Clas Groschinskys Minnesfonds MF2576
6 · The paper itself

Abstract

The COVID-19 pandemic was marked by successive waves of SARS-CoV-2 variants with distinct properties. The Omicron variant that emerged in late 2021 showed a major antigenic shift and rapidly spread worldwide. Since then, Omicron-derived variants have maintained their global dominance, for reasons that remain incompletely understood. We report that the original Omicron variant BA.1 evolved several traits that converged in facilitating viral spread. First, Omicron displayed an early replicative advantage over previous variants when grown in a reconstructed human nasal epithelium model. The increase in Omicron replication was more marked at the physiologically relevant temperature of 33°C found in human nasal passages. Omicron also caused a decrease in epithelial integrity, as measured by transepithelial electrical resistance and caspase-3 activation. Furthermore, Omicron caused a more marked loss of motile cilia at 33°C than other variants, suggesting a capacity to impair mucociliary clearance. Omicron induced a broad transcriptional downregulation of ciliary genes but only a limited upregulation of host innate defense genes at 33°C. The lower production of type I and type III interferons in epithelia infected by Omicron compared to those infected by the Delta variant, at 33°C as well as 37°C, confirmed the increased capacity of Omicron to evade the innate antiviral response. Thus, Omicron combined replication speed, motile cilia impairment, and limited induction of innate antiviral responses when propagated in nasal epithelia at physiological temperature. Omicron has the capacity to propagate rapidly but stealthily in the upper respiratory tract, which likely contributed to the evolutionary success of this SARS-CoV-2 variant. IMPORTANCE: The COVID-19 pandemic was initially characterized by a rapid succession of viral variants that emerged independently of each other, with each of these variants outcompeting the previous one. A major evolutionary shift occurred in late 2021, with the emergence of the highly divergent Omicron BA.1 variant. Since then, all the dominant SARS-CoV-2 variants have been derived from Omicron, for reasons that remain incompletely understood. Here, we compared the replication of SARS-CoV-2 variants in a human nasal epithelium model grown at 37°C and also at 33°C, a temperature that approximates that found in the nasal cavity. In this primary epithelial model, Omicron showed an early replicative advantage that was more marked at 33°C. However, Omicron triggered only a minimal antiviral interferon response at this temperature. Omicron could thus propagate rapidly while partly escaping the innate response at physiological nasal temperature, which helps account for the efficient dissemination of this variant worldwide.

Indexed as

COVID-19Nasal MucosaSARS-CoV-2Virus ReplicationCiliaHumansInterferonsTemperatureInterferonsinterferonmotile ciliamucosal immunitynasal epitheliumSARS-CoV-2

Identifiers

PMID41416837
PMCPMC12817898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.